메뉴 건너뛰기




Volumn 3, Issue 2, 2017, Pages 297-316

A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD

Author keywords

Bayesian analysis; Combination bronchodilator; Comparative efficacy; COPD; Indirect treatment comparison; LABA; LAMA; Meta analysis

Indexed keywords


EID: 85036577341     PISSN: 23641754     EISSN: 23641746     Source Type: Journal    
DOI: 10.1007/s41030-017-0048-0     Document Type: Article
Times cited : (32)

References (61)
  • 2
    • 1642493871 scopus 로고    scopus 로고
    • The role of long-acting bronchodilators in the management of stable COPD
    • COI: 1:CAS:528:DC%2BD2cXht1ekurw%3D, PID: 14718448
    • Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest. 2004;125(1):249–59. DOI: 10.1378/chest.125.1.249
    • (2004) Chest , vol.125 , Issue.1 , pp. 249-259
    • Tashkin, D.P.1    Cooper, C.B.2
  • 3
    • 84903602640 scopus 로고    scopus 로고
    • Long-acting bronchodilators in COPD: where are we now and where are we going?
    • Cazzola M, Page C. Long-acting bronchodilators in COPD: where are we now and where are we going? Breathe. 2014;10(2):111–20. DOI: 10.1183/20734735.014813
    • (2014) Breathe , vol.10 , Issue.2 , pp. 111-120
    • Cazzola, M.1    Page, C.2
  • 4
    • 33750115861 scopus 로고    scopus 로고
    • Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease (Review)
    • Appleton S, Poole P, Smith BJ, et al. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease (Review). Cochrane Database Syst Rev. 2006;3:CD001104. doi:10.1002/14651858.CD001104.pub2. DOI: 10.1002/14651858.CD001104.pub2
    • (2006) Cochrane Database Syst Rev , Issue.3
    • Appleton, S.1    Poole, P.2    Smith, B.J.3
  • 5
    • 2942692139 scopus 로고    scopus 로고
    • Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD
    • COI: 1:STN:280:DC%2BD2c3ntFWktg%3D%3D, PID: 15170026
    • Man WD, Mustfa N, Nikoletou D, et al. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax. 2004;59(6):471–6. DOI: 10.1136/thx.2003.019620
    • (2004) Thorax , vol.59 , Issue.6 , pp. 471-476
    • Man, W.D.1    Mustfa, N.2    Nikoletou, D.3
  • 6
    • 3543055330 scopus 로고    scopus 로고
    • Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease
    • PID: 15293609
    • O’Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J. 2004;24(1):86–94. DOI: 10.1183/09031936.04.00072703
    • (2004) Eur Respir J , vol.24 , Issue.1 , pp. 86-94
    • O’Donnell, D.E.1    Voduc, N.2    Fitzpatrick, M.3    Webb, K.A.4
  • 7
    • 0242577949 scopus 로고    scopus 로고
    • Contemporary management of chronic obstructive pulmonary disease: scientific review
    • COI: 1:CAS:528:DC%2BD3sXovVCjurc%3D, PID: 14600189
    • Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA. 2003;290(17):2301–12. DOI: 10.1001/jama.290.17.2301
    • (2003) JAMA , vol.290 , Issue.17 , pp. 2301-2312
    • Sin, D.D.1    McAlister, F.A.2    Man, S.F.3    Anthonisen, N.R.4
  • 8
    • 84963636152 scopus 로고    scopus 로고
    • A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 µg compared with tiotropium 18 µg in patients with COPD
    • Feldman G, Maltais F, Khindri S, et al. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 µg compared with tiotropium 18 µg in patients with COPD. Int J Chron Obstr Pulm Dis. 2016;11:719–30. DOI: 10.2147/COPD.S102494
    • (2016) Int J Chron Obstr Pulm Dis , vol.11 , pp. 719-730
    • Feldman, G.1    Maltais, F.2    Khindri, S.3
  • 9
    • 84868554172 scopus 로고    scopus 로고
    • Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
    • COI: 1:CAS:528:DC%2BC3sXhsFelt7o%3D, PID: 23060624
    • Kerwin E, Hebert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40(5):1106–14. DOI: 10.1183/09031936.00040712
    • (2012) Eur Respir J , vol.40 , Issue.5 , pp. 1106-1114
    • Kerwin, E.1    Hebert, J.2    Gallagher, N.3
  • 10
    • 2542603339 scopus 로고    scopus 로고
    • Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD
    • PID: 15218994
    • O’Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6):832–40. DOI: 10.1183/09031936.04.00116004
    • (2004) Eur Respir J , vol.23 , Issue.6 , pp. 832-840
    • O’Donnell, D.E.1    Fluge, T.2    Gerken, F.3
  • 11
    • 53749102775 scopus 로고    scopus 로고
    • A 4-year trial of tiotropium in chronic obstructive pulmonary disease
    • COI: 1:CAS:528:DC%2BD1cXht1WgsrjJ, PID: 18836213
    • Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–54. DOI: 10.1056/NEJMoa0805800
    • (2008) N Engl J Med , vol.359 , Issue.15 , pp. 1543-1554
    • Tashkin, D.P.1    Celli, B.2    Senn, S.3
  • 12
    • 80053065296 scopus 로고    scopus 로고
    • Disease severity and symptoms among patients receiving monotherapy for COPD
    • PID: 20886200
    • Dransfield MT, Bailey W, Crater G, Emmett A, O’Dell DM, Yawn B. Disease severity and symptoms among patients receiving monotherapy for COPD. Prim Care Respir J. 2011;20(1):46–53. DOI: 10.4104/pcrj.2010.00059
    • (2011) Prim Care Respir J , vol.20 , Issue.1 , pp. 46-53
    • Dransfield, M.T.1    Bailey, W.2    Crater, G.3    Emmett, A.4    O’Dell, D.M.5    Yawn, B.6
  • 13
    • 77953232163 scopus 로고    scopus 로고
    • The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD
    • COI: 1:CAS:528:DC%2BC3cXntlWqurw%3D, PID: 20381630
    • Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23(4):257–67. DOI: 10.1016/j.pupt.2010.03.003
    • (2010) Pulm Pharmacol Ther , vol.23 , Issue.4 , pp. 257-267
    • Cazzola, M.1    Molimard, M.2
  • 14
    • 61649115167 scopus 로고    scopus 로고
    • Formoterol and tiotropium compared with tiotropium alone for treatment of COPD
    • PID: 19229704
    • Tashkin DP, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD. 2009;6(1):17–25. DOI: 10.1080/15412550902724073
    • (2009) COPD , vol.6 , Issue.1 , pp. 17-25
    • Tashkin, D.P.1    Pearle, J.2    Iezzoni, D.3    Varghese, S.T.4
  • 15
    • 77952914041 scopus 로고    scopus 로고
    • Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms
    • PID: 20303247
    • van Noord JA, Aumann JL, Janssens E, et al. Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respir Med. 2010;104(7):995–1004. DOI: 10.1016/j.rmed.2010.02.017
    • (2010) Respir Med , vol.104 , Issue.7 , pp. 995-1004
    • van Noord, J.A.1    Aumann, J.L.2    Janssens, E.3
  • 16
    • 84880229392 scopus 로고    scopus 로고
    • Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study
    • COI: 1:CAS:528:DC%2BC2cXktlahsg%3D%3D, PID: 23722616
    • Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484–94. DOI: 10.1183/09031936.00200212
    • (2013) Eur Respir J , vol.42 , Issue.6 , pp. 1484-1494
    • Bateman, E.D.1    Ferguson, G.T.2    Barnes, N.3
  • 17
    • 84901766003 scopus 로고    scopus 로고
    • Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials
    • COI: 1:CAS:528:DC%2BC2cXhtVajtrnN, PID: 24835833
    • Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472–86. DOI: 10.1016/S2213-2600(14)70065-7
    • (2014) Lancet Respir Med , vol.2 , Issue.6 , pp. 472-486
    • Decramer, M.1    Anzueto, A.2    Kerwin, E.3
  • 18
    • 84925396337 scopus 로고    scopus 로고
    • Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial
    • PID: 25458157
    • Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108(12):1752–60. DOI: 10.1016/j.rmed.2014.10.002
    • (2014) Respir Med , vol.108 , Issue.12 , pp. 1752-1760
    • Maleki-Yazdi, M.R.1    Kaelin, T.2    Richard, N.3    Zvarich, M.4    Church, A.5
  • 19
    • 84877682284 scopus 로고    scopus 로고
    • Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease
    • COI: 1:CAS:528:DC%2BC3sXot1WnsLg%3D, PID: 23651244
    • Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013;14:49. DOI: 10.1186/1465-9921-14-49
    • (2013) Respir Res , vol.14 , pp. 49
    • Tashkin, D.P.1    Ferguson, G.T.2
  • 20
    • 85027923918 scopus 로고    scopus 로고
    • Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes
    • PID: 22222945
    • van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J. 2012;21(1):101–8. DOI: 10.4104/pcrj.2011.00102
    • (2012) Prim Care Respir J , vol.21 , Issue.1 , pp. 101-108
    • van der Molen, T.1    Cazzola, M.2
  • 21
    • 84872216479 scopus 로고    scopus 로고
    • Available at, Accessed 24 Oct 2016
    • ® Breezhaler® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002679/WC500151255.pdf. Accessed 24 Oct 2016.
    • ® Breezhaler® Summary of Product Characteristics
  • 22
    • 84968769959 scopus 로고    scopus 로고
    • Available at, 24 Oct
    • ®. Highlights of prescribing information. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207930s000lbl.pdf. Accessed 24 Oct 2016.
    • (2016) Highlights of Prescribing Information
  • 23
    • 85103353372 scopus 로고    scopus 로고
    • Summary of product characteristics. Available at, Accessed 24 Oct 2016
    • ®. Summary of product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002751/WC500168424.pdf. Accessed 24 Oct 2016.
  • 24
    • 85103346386 scopus 로고    scopus 로고
    • Highlights of prescribing information. Available at, Accessed 24 Oct 2016
    • ®. Highlights of prescribing information. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203975s000lbl.pdf. Accessed 24 Oct 2016.
  • 25
    • 77952118055 scopus 로고    scopus 로고
    • Available from,. Accessed 24 Oct 2016
    • ®. Summary of Product Characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003745/WC500178413.pdf. Accessed 24 Oct 2016.
    • Summary of Product Characteristics
  • 26
    • 77952118055 scopus 로고    scopus 로고
    • Available at, Accessed 24 Oct 2016
    • ®. Summary of Product Characteristics. Available at https://www.spiolto.com/public/assets/spiolto_spc_published.pdf. Accessed 24 Oct 2016.
    • Summary of Product Characteristics
  • 27
    • 79960720836 scopus 로고    scopus 로고
    • Available at, Accessed 24 Oct 2016
    • ®. Highlights of prescribing information. Available at http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Stiolto%20Respimat/stiolto.pdf. Accessed 24 Oct 2016.
    • Highlights of Prescribing Information
  • 30
    • 85010561746 scopus 로고    scopus 로고
    • Accessed 3 Oct 2016
    • Institute for Quality and Efficiency in Healthcare (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen). Dossier zur Nutzenbewertung gemäß § 35a SGB V. 2013. Available at https://www.g-ba.de/downloads/17-98-3528/2013-04-18_Anl2_6_Modul4.pdf. Accessed 3 Oct 2016.
    • (2013) Dossier Zur Nutzenbewertung gemäß § 35A SGB
  • 31
    • 26944454062 scopus 로고    scopus 로고
    • Simultaneous comparison of multiple treatments: combining direct and indirect evidence
    • PID: 16223826
    • Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331(7521):897–900. DOI: 10.1136/bmj.331.7521.897
    • (2005) BMJ , vol.331 , Issue.7521 , pp. 897-900
    • Caldwell, D.M.1    Ades, A.E.2    Higgins, J.P.3
  • 32
    • 52649100566 scopus 로고    scopus 로고
    • Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons
    • PID: 18489499
    • Jansen JP, Crawford B, Bergman G, Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health. 2008;11(5):956–64. DOI: 10.1111/j.1524-4733.2008.00347.x
    • (2008) Value Health , vol.11 , Issue.5 , pp. 956-964
    • Jansen, J.P.1    Crawford, B.2    Bergman, G.3    Stam, W.4
  • 33
    • 5044221416 scopus 로고    scopus 로고
    • Combination of direct and indirect evidence in mixed treatment comparisons
    • COI: 1:STN:280:DC%2BD2crhvFCqug%3D%3D, PID: 15449338
    • Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105–24. DOI: 10.1002/sim.1875
    • (2004) Stat Med , vol.23 , Issue.20 , pp. 3105-3124
    • Lu, G.1    Ades, A.E.2
  • 35
    • 84877131237 scopus 로고    scopus 로고
    • Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study
    • COI: 1:CAS:528:DC%2BC2cXhsFCltL8%3D, PID: 24429126
    • Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199–209. DOI: 10.1016/S2213-2600(13)70052-3
    • (2013) Lancet Respir Med , vol.1 , Issue.3 , pp. 199-209
    • Wedzicha, J.A.1    Decramer, M.2    Ficker, J.H.3
  • 36
    • 84885734407 scopus 로고    scopus 로고
    • Tiotropium respimat inhaler and the risk of death in COPD
    • COI: 1:CAS:528:DC%2BC3sXhs1CgsbzE, PID: 23992515
    • Wise RA, Anzueto A, Cotton D, et al. Tiotropium respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491–501. DOI: 10.1056/NEJMoa1303342
    • (2013) N Engl J Med , vol.369 , Issue.16 , pp. 1491-1501
    • Wise, R.A.1    Anzueto, A.2    Cotton, D.3
  • 37
    • 84884996543 scopus 로고    scopus 로고
    • Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis
    • PID: 24093477
    • Cope S, Donohue JF, Jansen JP, et al. Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis. Respir Res. 2013;14:100. DOI: 10.1186/1465-9921-14-100
    • (2013) Respir Res , vol.14 , pp. 100
    • Cope, S.1    Donohue, J.F.2    Jansen, J.P.3
  • 38
    • 84941565154 scopus 로고    scopus 로고
    • ®) trial: spirometry outcomes
    • PID: 26369563
    • ®) trial: spirometry outcomes. Respir Res. 2015;16:107. DOI: 10.1186/s12931-015-0269-4
    • (2015) Respir Res , vol.16 , pp. 107
    • Anzueto, A.1    Wise, R.2    Calverley, P.3
  • 39
    • 20144382361 scopus 로고    scopus 로고
    • Minimal clinically important differences in COPD lung function
    • PID: 17136971
    • Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2(1):111–24. DOI: 10.1081/COPD-200053377
    • (2005) COPD , vol.2 , Issue.1 , pp. 111-124
    • Donohue, J.F.1
  • 40
    • 20144362569 scopus 로고    scopus 로고
    • St. George’s respiratory questionnaire: MCID
    • PID: 17136966
    • Jones PW. St. George’s respiratory questionnaire: MCID. COPD. 2005;2(1):75–9. DOI: 10.1081/COPD-200050513
    • (2005) COPD , vol.2 , Issue.1 , pp. 75-79
    • Jones, P.W.1
  • 41
    • 84921459850 scopus 로고    scopus 로고
    • Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study
    • PID: 25404569
    • Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178. DOI: 10.1186/1471-2466-14-178
    • (2014) BMC Pulm Med. , vol.14 , pp. 178
    • Singh, D.1    Jones, P.W.2    Bateman, E.D.3
  • 42
    • 84965085606 scopus 로고    scopus 로고
    • Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study
    • PID: 25756831
    • D’Urzo AD, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2014;15:123. DOI: 10.1186/s12931-014-0123-0
    • (2014) Respir Res , vol.15 , pp. 123
    • D’Urzo, A.D.1    Rennard, S.I.2    Kerwin, E.M.3
  • 43
    • 20144372614 scopus 로고    scopus 로고
    • The MCID of the transition dyspnea index is a total score of one unit
    • PID: 17136969
    • Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD. 2005;2(1):99–103. DOI: 10.1081/COPD-200050666
    • (2005) COPD , vol.2 , Issue.1 , pp. 99-103
    • Mahler, D.A.1    Witek, T.J.2
  • 44
    • 84962324214 scopus 로고    scopus 로고
    • Dual bronchodilator therapy with umeclidinium/vilanterol versus tiotropium plus indacaterol in chronic obstructive pulmonary disease: a randomized controlled trial
    • COI: 1:CAS:528:DC%2BC28Xltlags78%3D
    • Kalberg C, O’Dell D, Galkin D, Newlands A, Fahy WA. Dual bronchodilator therapy with umeclidinium/vilanterol versus tiotropium plus indacaterol in chronic obstructive pulmonary disease: a randomized controlled trial. Drugs R&D. 2016;16(2):217–27. DOI: 10.1007/s40268-016-0131-2
    • (2016) Drugs R&D. , vol.16 , Issue.2 , pp. 217-227
    • Kalberg, C.1    O’Dell, D.2    Galkin, D.3    Newlands, A.4    Fahy, W.A.5
  • 46
    • 84925781229 scopus 로고    scopus 로고
    • Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study
    • PID: 25677679
    • Buhl R, Gessner C, Schuermann W, et al. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. Thorax. 2015;70(4):311–9. DOI: 10.1136/thoraxjnl-2014-206345
    • (2015) Thorax , vol.70 , Issue.4 , pp. 311-319
    • Buhl, R.1    Gessner, C.2    Schuermann, W.3
  • 47
    • 84958166671 scopus 로고    scopus 로고
    • Efficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis
    • PID: 26490732
    • Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016;71(1):15–25. DOI: 10.1136/thoraxjnl-2014-206732
    • (2016) Thorax , vol.71 , Issue.1 , pp. 15-25
    • Oba, Y.1    Sarva, S.T.2    Dias, S.3
  • 48
    • 84966586570 scopus 로고    scopus 로고
    • A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD
    • PID: 26923629
    • Calzetta L, Rogliani P, Matera MG, Cazzola M. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016;149(5):1181–96. DOI: 10.1016/j.chest.2016.02.646
    • (2016) Chest , vol.149 , Issue.5 , pp. 1181-1196
    • Calzetta, L.1    Rogliani, P.2    Matera, M.G.3    Cazzola, M.4
  • 49
    • 77956695739 scopus 로고    scopus 로고
    • Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations
    • PID: 20565728
    • Glaab T, Vogelmeier C, Buhl R. Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir Res. 2010;11:79. DOI: 10.1186/1465-9921-11-79
    • (2010) Respir Res , vol.11 , pp. 79
    • Glaab, T.1    Vogelmeier, C.2    Buhl, R.3
  • 50
    • 85010735445 scopus 로고    scopus 로고
    • The importance of inhaler devices in the treatment of COPD
    • Bonini M, Usmani OS. The importance of inhaler devices in the treatment of COPD. COPD Res Pract. 2015;1:9. DOI: 10.1186/s40749-015-0011-0
    • (2015) COPD Res Pract , vol.1 , pp. 9
    • Bonini, M.1    Usmani, O.S.2
  • 51
    • 84949422610 scopus 로고    scopus 로고
    • Dry powder inhalers and the right things to remember: a concept review
    • Dal Negro RW. Dry powder inhalers and the right things to remember: a concept review. Multidiscip Respir Med. 2015;10(1):13. DOI: 10.1186/s40248-015-0012-5
    • (2015) Multidiscip Respir Med , vol.10 , Issue.1 , pp. 13
    • Dal Negro, R.W.1
  • 52
    • 38449089896 scopus 로고    scopus 로고
    • Use of respimat soft mist inhaler in COPD patients
    • COI: 1:CAS:528:DC%2BD28Xhtlars7jO
    • Anderson P. Use of respimat soft mist inhaler in COPD patients. Int J Chron Obstr Pulm Dis. 2006;1(3):251–9.
    • (2006) Int J Chron Obstr Pulm Dis , vol.1 , Issue.3 , pp. 251-259
    • Anderson, P.1
  • 53
    • 84957604022 scopus 로고    scopus 로고
    • Acceptability and preference of three inhalation devices assessed by the handling questionnaire in asthma and COPD patients
    • Dal Negro RW, Povero M. Acceptability and preference of three inhalation devices assessed by the handling questionnaire in asthma and COPD patients. Multidiscip Respir Med. 2016;11:7. DOI: 10.1186/s40248-016-0044-5
    • (2016) Multidiscip Respir Med , vol.11 , pp. 7
    • Dal Negro, R.W.1    Povero, M.2
  • 54
    • 84916942283 scopus 로고    scopus 로고
    • ® dry powder inhaler over a commonly used single-dose capsule dry powder inhaler by inhalation device-naive Japanese volunteers aged 40 years or older
    • PID: 25525354
    • ® dry powder inhaler over a commonly used single-dose capsule dry powder inhaler by inhalation device-naive Japanese volunteers aged 40 years or older. Int J Chron Obstruct Pulmon Dis. 2014;9:1365–75. DOI: 10.2147/COPD.S72762
    • (2014) Int J Chron Obstruct Pulmon Dis , vol.9 , pp. 1365-1375
    • Komase, Y.1    Asako, A.2    Kobayashi, A.3    Sharma, R.4
  • 55
    • 84933535700 scopus 로고    scopus 로고
    • Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD: a randomised, cross-over, multicentre study
    • PID: 25927321
    • Pascual S, Feimer J, De Soyza A, et al. Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD: a randomised, cross-over, multicentre study. NPJ Prim Care Respir Med. 2015;25:15018. DOI: 10.1038/npjpcrm.2015.18
    • (2015) NPJ Prim Care Respir Med , vol.25 , pp. 15018
    • Pascual, S.1    Feimer, J.2    De Soyza, A.3
  • 56
    • 85017170003 scopus 로고    scopus 로고
    • Device errors in asthma and COPD: systematic literature review and meta-analysis
    • PID: 28373682
    • Chrystyn H, van der Palen J, Sharma R, et al. Device errors in asthma and COPD: systematic literature review and meta-analysis. NPJ Prim Care Respir Med. 2017;27(1):22. DOI: 10.1038/s41533-017-0016-z
    • (2017) NPJ Prim Care Respir Med , vol.27 , Issue.1 , pp. 22
    • Chrystyn, H.1    van der Palen, J.2    Sharma, R.3
  • 57
    • 84947027095 scopus 로고    scopus 로고
    • New developments in inhaler devices within pharmaceutical companies: a systematic review of the impact on clinical outcomes and patient preferences
    • PID: 26439177
    • Ninane V, Vandevoorde J, Cataldo D, et al. New developments in inhaler devices within pharmaceutical companies: a systematic review of the impact on clinical outcomes and patient preferences. Respir Med. 2015;109(11):1430–8. DOI: 10.1016/j.rmed.2015.09.013
    • (2015) Respir Med , vol.109 , Issue.11 , pp. 1430-1438
    • Ninane, V.1    Vandevoorde, J.2    Cataldo, D.3
  • 58
    • 84892452314 scopus 로고    scopus 로고
    • A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study
    • PID: 24438744
    • Chapman KR, Beeh KM, Beier J, et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med. 2014;14:4. DOI: 10.1186/1471-2466-14-4
    • (2014) BMC Pulm Med , vol.14 , pp. 4
    • Chapman, K.R.1    Beeh, K.M.2    Beier, J.3
  • 59
    • 84960540618 scopus 로고    scopus 로고
    • Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting beta2-agonists: a systematic review and network meta-analysis
    • COI: 1:CAS:528:DC%2BC2sXntFOrur4%3D, PID: 26746383
    • Schlueter M, Gonzalez-Rojas N, Baldwin M, Groenke L, Voss F, Reason T. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting beta2-agonists: a systematic review and network meta-analysis. Ther Adv Respir Dis. 2016;10(2):89–104. DOI: 10.1177/1753465815624612
    • (2016) Ther Adv Respir Dis , vol.10 , Issue.2 , pp. 89-104
    • Schlueter, M.1    Gonzalez-Rojas, N.2    Baldwin, M.3    Groenke, L.4    Voss, F.5    Reason, T.6
  • 60
    • 84878276436 scopus 로고    scopus 로고
    • Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study
    • PID: 20639294
    • Nuesch E, Trelle S, Reichenbach S, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ. 2010;341:c3515. DOI: 10.1136/bmj.c3515
    • (2010) BMJ , vol.341 , pp. c3515
    • Nuesch, E.1    Trelle, S.2    Reichenbach, S.3
  • 61
    • 0033667445 scopus 로고    scopus 로고
    • Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature
    • COI: 1:STN:280:DC%2BD3M%2FltV2iug%3D%3D, PID: 11106885
    • Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53(11):1119–29. DOI: 10.1016/S0895-4356(00)00242-0
    • (2000) J Clin Epidemiol , vol.53 , Issue.11 , pp. 1119-1129
    • Sterne, J.A.1    Gavaghan, D.2    Egger, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.